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Abstract
Introduction: Docetaxel is a semisynthetic taxane commonly used in solid tumour oncology. Its
pharmacokinetics has been widely studied, and it is well established that it is metabolized to
pharmacologically inactive products by the cytochrome P450 3A iso-enzymes. However, there have
been few reports of the consequences of drug interactions between taxanes and other drugs
metabolized by the cytochrome P450 pathway. To the best of our knowledge, this is the first case
report of the potentially life-threatening interaction that can occur between docetaxel and the
protease inhibitors lopinavir and ritonavir.
Case presentation: A 30-year-old Caucasian woman presented with symptoms suggestive of
severe docetaxel toxicity, that is, prolonged myelosuppression, grade 4 mucositis and desquamating
rash, following the commencement of post-exposure prophylaxis for a needlestick injury. She had
previously received docetaxel chemotherapy with minimal side effects.
Conclusion: This case report highlights a probable and novel drug interaction between docetaxel
and lopinavir and/or ritonavir, which is largely unreported in the medical literature. Even though
these interactions may be more relevant in the field of HIV medicine, knowledge of these interactions
is also beneficial to oncologists and dermatologists, as well as those providing acute medical care.
Introduction
Docetaxel is a semisynthetic taxane that is widely used in
solid tumour oncology including breast, gastric, non-small
cell lung and prostate tumour types [1]. Docetaxel is
associated with side effects such as fatigue, nausea,
vomiting, alopecia, myalgia, skin rashes, oedema, myelo-
suppression and mucositis [2]. However, docetaxel is
usually well tolerated at the dose administered,
particularly in patients with no significant comorbidities
[2,3]. It acts by inducing microtubular stability by binding
tubulin, thus preventing depolymerisation and the normal
dynamics of the microtubular network. This results in cell
cycle arrest and apoptosis [1,4]. Its pharmacokinetics have
been widely studied, and it is well established that it is
metabolized to pharmacologically inactive products by
the cytochrome P450 3A isoenzymes [5]. Despite this,
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(page number not for citation purposes)little has been published regarding the potential interac-
tions of docetaxel with other drugs, and the consequences
of such interactions.
Case presentation
A 30-year-old Caucasian woman with no significant past
medical history underwent a wide local excision and
sentinel lymph node biopsy for a 15 mm grade 2 invasive
ductal carcinoma of the right breast. She was subsequently
treated with adjuvant chemotherapy with a modified
fluorouracil, epirubicin, cyclophosphamide and docetaxel
(Taxotere, Sanofi Aventis) (FEC-T) regimen. The treatment
consisted of fluorouracil 600 mg/m
2, epirubicin 75 mg/m
2
and cyclophosphamide 600 mg/m
2 every 21 days for three
cycles, followed by sequential three-cycle treatments of
100 mg/m
2 of docetaxel every 21 days. She received
primary prophylaxis with pegylated granulocyte-colony
stimulating factor (GCSF) regimen (pegfilgrastim 6 mg
subcutaneously 24 hours after chemotherapy). She toler-
ated the first two cycles of docetaxel well with minimal
toxicity (grade 2 fatigue, grade 1-2 nausea and grade 1
neuropathy).
Following the fifth cycle of chemotherapy (second cycle
of single agent docetaxel), she sustained a low-risk
needlestick injury, with no contact with blood, from
her HIV-positive partner. She had previously tested
negative in regular HIV tests, most recently 3 months
prior to admission, but sought advice from the centre she
usually attended. She was commenced on post-exposure
prophylaxis (PEP) with Combivir (lamivudine 150 gm
and zidovudine 300 mg twice daily, GlaxoSmithKline)
and Kaletra (lopinavir 400 mg and ritonavir 100 mg
twice daily, Abbott) a week before her third cycle of
docetaxel.
She received her third cycle uneventfully with standard
steroid prophylaxis (dexamethasone 8 mg twice daily for
3 days commencing the day before treatment). Routine
blood tests taken prior to her third cycle revealed a normal
full blood count and differential, normal renal function
and normal hepatic function. She was admitted on day 6
of the cycle with febrile neutropenia, grade 2 mucositis
and grade 2 arthralgia and myalgia. Apart from her recent
docetaxel chemotherapy with concomitant steroids and
antiretroviral prophylaxis (lamivudine, zidovudine, lopi-
navir and ritonavir), the patient was taking no other
medications. Total white cell count (WCC) was 1.3 × 10
9/
litre with a neutrophil count of 0.6 × 10
9/litre on
admission, which decreased further to 0.005 × 10
9/litre
the following day. Renal and hepatic function tests,
including albumin, were within the normal range, and
remained within the normal range throughout her
admission. She was started on broad spectrum antibiotics
with tazocin and gentamycin and antifungal prophylaxis
with fluconazole 50 mg daily. Blood cultures sent on
admission grew a fully sensitive Cellumonas species.
Subsequent blood cultures tested negative.
Over the next few days, her mucositis worsened to grade 4.
She continued to have a swinging pyrexia with persistent
grade 4 neutropenia, and was started on teicoplanin,
which was then followed by meropenem with continued
teicoplanin and gentamicin as per local protocol. The
patient received additional daily GCSF and the flucona-
zole was increased to 200 mg daily. Her neutrophil count
recovered to 2.1 × 10
9/litre on day 7 of her admission. She
subsequently developed diarrhea with negative cultures,
and on day 10 developed facial swelling and erythema.
The combivir was switched to an alternative antiretroviral
due to ongoing myelosuppression, but the patient decided
to stop taking all antiretrovirals at this point. She then
developed a florid rash on her hands and feet (Figures 1
and 2). Due to her ongoing pyrexia and grade 4 mucositis,
her fluconazole medication was changed to caspofungin.
A high resolution computerised tomography (CT) scan of
the patient’s thorax tested negative for disseminated fungal
infection. Meanwhile, topical treatment was prescribed for
her face, hands and feet.
Two weeks after admission, the patient’s condition failed
to improve. Ganciclovir was added to her medication to
address possible cytomegalovirus (CMV) related mucosi-
tis. She was also started on total parenteral nutrition. Both
CT sinuses and echocardiography performed on the
patient yielded negative results, but results of her
oesophagogastroduodenoscopy (OGD) and flexible sig-
moidoscopy revealed widespread ulceration in the eso-
phagus and gastric antrum that was biopsied. Meanwhile,
a galactomannan antigen assay for Aspergillus and fungal
cultures from her biopsies were negative.
Figure 1. Appearance of feet (Day 11).
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improve, associated with an improvement in the WCC
and resolution of the mucositis. Apart from a mild upper
gastrointestinal bleed on day 20, which was managed
conservatively, the patient’s recovery was sustained. She
was finally discharged home well 26 days after admission.
Discussion
The striking feature of this case was the severity and
duration of mucositis, skin reaction, and neutropenia in
the presence of normal hepatic function in an individual
who had previously tolerated docetaxel-containing che-
motherapy. The temporal relationships in this case suggest
several aetiological options:
A. A sudden change in the individual’s ability to
metabolise docetaxel due to intrinsic factors.
B. An adverse reaction either to the retroviral medications
or to other supportive medications.
C. A drug interaction between docetaxel and other
medications.
Data regarding the pharmaceutical agents discussed below
has been obtained from online sources including the
British National Formulary (http://www.bnf.org), the
National Cancer Institute (http://www.cancer.gov) and
Micromedex (www.micromedex.com).
In the absence of altered organ function, as the patient had
normal liver and renal function throughout, option A
would appear unlikely. The patient was started on several
new medications within a short time interval, so option B
deservesfurtherconsideration.Thepatientreceived13days
of PEP before her admission. The combination of
lamivudine and zidovudine is unusually known to cause
skin rashes in 9% and neutropenia in 7.2% of patients
receiving treatment. The combination of lopinavir and
ritonavir can be associated with allergic reactions (<2%),
facial oedema (<2%), skin rash (2%), stomatitis and
oesophagitis (<2%), and neutropenia in combination
with nucleoside reverse transcriptase inhibitors (4%). In
the absence of any mitigating factor, it is unusual for a
patientwithnopreviousexperienceoftoxicityinanyorgan
system to suddenly experience such severe toxicity.
It is, however, possible that other medications received
during the hospital admission, while not the primary
cause of the side effects observed, prolonged or exacer-
bated the patient’s toxicity. Examples of this effect would
be the association of stomatitis with tazocin and
gentamycin, of colitis and diarrhoea with various anti-
biotics, of neutropenia with teicoplanin and ganciclovir,
and of CYP450 3A4 inhibition with fluconazole. It should
be noted that the patient’s rash had neither the distribu-
tion nor characteristic features of Stevens-Johnson
syndrome.
Option C is the most likely reason for the toxicity observed
because many of the clinical features of the patient’s
presentation, that is, the onset and duration of neutrope-
nia; development of stomatitis, mucositis and colitis;
facial oedema; and characteristics and distribution of the
skin rash, resembled severe toxicity to docetaxel. Among
patients receiving 100 mg/m
2 docetaxel with normal liver
function and appropriate premedication, febrile neutro-
penia occurs in up to 11% of cases, severe stomatitis in
7.4% and fluid retention in 64%. Two other factors are
implicated in the observed drug reaction: (1) the
cytochrome P450 system is both essential for the
metabolism of docetaxel into inactive metabolites; and
(2) the cytochrome P450 system can be inhibited by the
addition of protease inhibitors (PIs).
Antiretroviral therapies, PIs in particular, are known to
modulate the cytochrome P450 system. Ritonavir-boosted
PI combinations were specifically introduced to exploit
the inhibition of cytochrome enzymes by ritonavir,
thereby increasing the levels of other PIs such as lopinavir
by reducing hepatic metabolism.
As taxanes such as docetaxel are also metabolized by the
cytochrome P450 system, the potential for interactions is
significant. Pharmacokinetic interactions from altered
metabolism via modulation of the cytochrome P450
pathway may result in drug accumulation and increased
toxicity or reduced efficacy of one or both drugs. In the
absence of pharmacokinetic interactions, the two drugs
may still produce clinically relevant pharmacodynamic
interactions due to antagonism, additive effects or synergy
Figure 2. Desquamating rash on hands (Day 11).
Page 3 of 5
(page number not for citation purposes)
Journal of Medical Case Reports 2009, 3:8866 http://jmedicalcasereports.com/jmedicalcasereports/article/view/8866[6]. A recent study discussed the potential for interactions
between antineoplastic agents and highly active antire-
troviral therapy (HAART) [5]. Evidence also suggest that
patients who receive chemotherapy in conjunction with
HAART have improved response rates and survival rates
compared with patients who undergo chemotherapy
alone [7].
The cytochrome P450 system is essential to the metabo-
lism of docetaxel, and the CYP3A4 route is the sole
mechanism of the conversion of docetaxel to several
inactive metabolites [8]. It was previously noted that
administration of the PI ritonavir in mice increased the
plasma levels of oral docetaxel by up to 50 times. The
authors thus suggested that the co-administration of
ritonavir may be a novel way to increase the bioavailability
of oral docetaxel [9].
It is interesting to note that a recent study assessing
treatment-related effects via the addition of ritonavir to
docetaxel in androgen-independent prostate cancer cell
lines revealed that the addition of ritonavir enhanced
both the antiproliferative and the proapoptotic effects
of docetaxel in DU145 cells [10]. Further analysis of
quantitative real-time polymerase chain reaction (PCR)
showed that ritonavir completely suppressed docetaxel-
induced CYP3A4 expression. The same observation was
seen in tumour xenografts in mice. Once again, the
addition of ritonavir to chemotherapy was advocated as
a potential therapeutic strategy, due to its ability to
potentiate levels of docetaxel.
To the best of our knowledge, there is only one other
published case report of a patient treated with docetaxel
that describes phenomena similar to those we observed
in our patient. The report was of a patient undergoing
chemotherapy for metastatic breast cancer with low dose
docetaxel 36 mg/m
2 and trastuzumab, concurrently
treated with the PI nelfinavir. The patient, who was
hospitalized on day three of her first cycle of treatment due
to severe neutropenic sepsis and acute respiratory distress
syndrome (ARDS), subsequently died [11]. There are also
reports of similar phenomena being observed in patients
treated with paclitaxel and HAART [11,12], although the
consequences may not appear as severe, possibly because
the metabolism of paclitaxel is less dependent on the
CYP3A4 pathway [5].
More data on the consequences of interactions between
HAART and non-taxane containing regimens exist. For
example, a recent trial compared the toxicity associated
with PI-containing HAART and non-PI HAART in patients
receiving infusional cyclophosphamide, doxorubicin
and etoposide (CDE) for AIDS-related non-Hodgkin’s
lymphoma. While no statistically significant difference
was found between the two groups in terms of overall
survival or response rates, the PI-containing arm experi-
enced more grade 3 and 4 infections (48% versus 25%, c
2
test p = 0.0025), more prolonged neutropenia and more
delays on chemotherapy [13].
Further support for a potential drug interaction between
docetaxel and PIs can be derived from the published
literature suggesting interactions with other CYP3A4
modulators. Whilst formal clinical studies in this setting
are sparse, in vivo and in vitro studies suggest that the
metabolism of docetaxel can be modified by many drugs
that induce or inhibit cytochrome P450 3A4, including
erythromycin and ketoconazole [14,15], with the erythro-
mycin breath test advocated as a method of quantifying
the degree of CYP3A4 activity following administration of
docetaxel [15].
In order to quantify the strength of the association, the
authors used the Drug Interaction Probability Scale
(DIPS), designed to assess the probability of a causal
relationship between a potential drug reaction and an
event, and specifically of a drug-drug interaction [16].
Using the data presented above, a score of 5 classified this
as a probable causal relationship.
Conclusion
After other possible aetiologies had been excluded,
our final diagnosis was one of severe docetaxel toxicity
precipitated by the concomitant administration of PIs as
part of PEP. The mechanism of this potential novel drug-
drug interaction was concluded to be as a result of the
inhibition of CYP3A4 causing an increased and prolonged
exposure of normal tissues to docetaxel in its active form.
We initially thought this diagnosis was unlikely as the
patient had previously tolerated two cycles at the same
dose. However, the patient’s main presenting features of
prolonged febrile neutropenia with profound myelosup-
pression, severe mucositis, initial severe myalgia, and
severe skin toxicity were entirely consistent with a reaction
to docetaxel. We explored a possible causative link
between the patient’s severe toxicity on this occasion and
her concurrent medication with PEP, and found no other
predisposing features for docetaxel toxicity, such as
abnormal liver function tests [3,17].
This case report highlights the severity of the potential
interaction between docetaxel and PI-based antiretroviral
therapy, with lopinavir and ritonavir in this instance.
While these interactions are perhaps well known to
clinicians treating HIV-associated malignancies, they are
less obvious when antiretrovirals are prescribed as part
of PEP. Clinicians should be aware of this reaction and
routinely avoid the combination of PIs with taxanes.
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but further studies are required. The relative benefits of
PEP need to be considered very carefully in a patient
undergoing concomitant taxane-based chemotherapy.
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